trial · primary record
Belzutifan
Pheochromocytoma/Paraganglioma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 355 |
| Primary completion | 2032-11-18 |
| Primary endpoint | Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT04924075 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:59.016Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04924075
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Belzutifan · approval
- Belzutifan · compound